We are live on ! Find out more
BIOTW

Biotech Acquisition Company Warrant
BIOTW

Delisted

BIOTW was delisted on the 2nd of February, 2023.

Back to rankings

56 hedge funds and large institutions have $8.44M invested in Biotech Acquisition Company Warrant in 2021 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

425% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 4

44% more funds holding

Funds holding: 39 → 56 (+17)

30% more capital invested

Capital invested by funds: $6.51M → $8.44M (+$1.93M)

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

Holders
56
Holders Change
+17
Holders Change %
+43.59%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
5
Reduced
8
Closed
4
Calls
$5.78M
Puts
–
Net Calls
+$5.78M
Net Calls Change
+$4.42M

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$736K
2
HIM
HGC Investment Management
Ontario, Canada
+$382K
3
MF
Magnetar Financial
Illinois
+$153K
4
QGA
Q Global Advisors
Texas
+$87.3K
5
AC
Antara Capital
New York
+$76.3K

Top Sellers

Rank Fund Capital Flow
1
DCM
DG Capital Management
New York
-$148K
2
Nomura Holdings
Nomura Holdings
Japan
-$127K
3
Citadel Advisors
Citadel Advisors
Florida
-$122K
4
RA
Ramius Advisors
New York
-$119K
5
MI
MMCAP International
Cayman Islands
-$111K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
Radcliffe Capital Management
Pennsylvania
$2M – – –
AC
2
Aristeia Capital
Connecticut
$668K +$736K +1,060,504 New
LP
3
LMR Partners
United Kingdom
$492K – – –
SCM
4
Segantii Capital Management
Hong Kong
$492K +$34.7K +50,000 New
HIM
5
HGC Investment Management
Ontario, Canada
$364K +$382K +550,950 New
Citadel Advisors
6
Citadel Advisors
Florida
$323K -$122K -175,149 -26%
CCP
7
Corbin Capital Partners
New York
$306K – – –
RA
8
Ramius Advisors
New York
$299K -$119K -171,199 -27%
AA
9
AQR Arbitrage
Connecticut
$261K – – –
LA
10
Linden Advisors
New York
$214K – – –
KCM
11
Kingstown Capital Management
New York
$198K – – –
SRCM
12
Sage Rock Capital Management
New York
$189K – – –
ACM
13
Atalaya Capital Management
New York
$181K – – –
Blackstone Inc
14
Blackstone Inc
New York
$165K – – –
BFM
15
Boothbay Fund Management
New York
$157K +$1.49K +2,150 +16%
MF
16
Magnetar Financial
Illinois
$144K +$153K +221,192 New
PAMP
17
Polar Asset Management Partners
Ontario, Canada
$129K -$9.92K -14,300 -7%
PC
18
Periscope Capital
Ontario, Canada
$112K -$54.3K -78,300 -32%
QGA
19
Q Global Advisors
Texas
$109K +$87.3K +125,880 +325%
SC
20
Sculptor Capital
New York
$94K – – –
TCM
21
Tenor Capital Management
New York
$93K – – –
MI
22
MMCAP International
Cayman Islands
$92K -$111K -160,000 -53%
DKCM
23
Davidson Kempner Capital Management
New York
$90K – – –
TI
24
Telemetry Investments
New York
$90K +$26.8K +38,669 +39%
FTCM
25
Fir Tree Capital Management
New York
$82K -$17.1K -24,591 -16%
1
2 3

BIOTW Hedge Fund Activity: Q4 2021 in Review

56 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q4 2021, worth a combined $8.44M — up 30% from $6.51M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new BIOTW positions and 4 closed out — a net gain of 17 holders — while 5 added to existing stakes and 8 trimmed.

The largest buyer was Aristeia Capital, opening a new position worth an estimated $736K. The largest seller was DG Capital Management, exiting entirely with an estimated $148K sold.

  • 56 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q4 2021, up from 39 in Q3 2021.
  • Funds reported $8.44M of Biotech Acquisition Company Warrant stock for Q4 2021, up 30% quarter-over-quarter.
  • 21 funds opened new Biotech Acquisition Company Warrant positions in Q4 2021 and 4 closed out, a net change of +17 holders.
  • The largest Biotech Acquisition Company Warrant buyer in Q4 2021 was Aristeia Capital, an estimated $736K added.
  • The largest Biotech Acquisition Company Warrant seller in Q4 2021 was DG Capital Management, an estimated $148K sold.

Based on aggregated 13F filings for Q4 2021.